At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 6,000 target
Drug / intervention
Osimertinib +4 moredrug
Likely dose
Alectinib 150 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.
In Brief
A Phase 2 clinical trial evaluating Osimertinib, Alectinib 150 MG, and 3 other interventions for Non Small Cell Lung Cancer and 4 related conditions. Currently recruiting, targeting 6,000 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROS1 Gene Mutation, MET Gene Mutation
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
20212022202320242025202620272028
First PostedMar 2020
Enrollment StartApr 2020
TodayJul 2026
Primary CompletionDec 2026
Study CompletionDec 2027
First PostedMar 26, 2020
Enrollment StartApr 16, 2020
Primary CompletionDec 24, 2026
Study CompletionDec 24, 2027
TodayJul 1, 2026
Enrollment to primary: 6.7 yearsPosted 6.3 years agoPrimary completion in 6 months
Interventions
Osimertinibdrug
Osimertinib 80mg, po, qd;
Alectinib 150 MGdrug
Alectinib 600mg, po, qd; Lorlatinib, 100mg, po, qd;
Crizotinib 250 MGdrug
Crizotinib 250 MG po bid.
Savolitinib, Crizotinib.drug
Savolitinib, 300mg po qd.
Chemotherapydrug
500mg, ivgtt, every 21day.